A physiologically based pharmacokinetic model for capreomycin

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 926-934

  Reisfeld, Brad ^a   Metzler, C P ^a,c   Lyons, M A ^a   Mayeno, A N ^a   Brooks, E J ^b   DeGroote, M A ^b  

^a Engineering Research Center and Hydraulics Laboratory   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; CYCLOPEPTIDE; GENTAMICIN; NETILMICIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; KIDNEY; LOW DRUG DOSE; MONTE CARLO METHOD; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTITUBERCULAR AGENTS; BAYES THEOREM; BIOLOGICAL TRANSPORT; CAPREOMYCIN; COMPUTER SIMULATION; FEMALE; HUMANS; KIDNEY; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MONTE CARLO METHOD; TISSUE DISTRIBUTION;

EID: 84856077172     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05180-11     Document Type: Article

References (52)

1. Allen BC, Hack CE, Clewell HJ. 2007. Use of Markov chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methyl-mercury to estimate exposures in US women of childbearing age. Risk Anal. 27:947-959. (Pubitemid 47631881)
2. Alonso IG, Lanao JM, Saez MC, Dominguez-Gil AA, Dominguez-Gil A. 1987. Non-linear tissue binding of amikacin in rats: the effect of renal impairment. Eur. J. Drug Metab. Pharmacokinet. 12:193-201. (Pubitemid 18000997)
3. Black HR, Griffith RS, Brickler JF. 1963. Preliminary laboratory studies with capreomycin. Antimicrob. Agents Chemother. 161:522-529.
4. Black HR, Griffith RS, Peabody AM. 1966. Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann. N. Y. Acad. Sci. 135:974-982.
5. Bois, F. 24 February 2009, posting date. MCSim manual, version 5.3.0. Free Software Foundation, Inc. https://www.gnu.org/software/mcsim/mcsim.html.
6. Bois FY. 1999. Analysis of PBPK models for risk characterization. Ann. N. Y. Acad. Sci. 895:317-337. (Pubitemid 30040562)
7. Bois FY, et al. 1996. Population toxicokinetics of tetrachloroethylene. Arch. Toxicol. 70:347-355. (Pubitemid 26095130)
8. Bois FY, Jamei M, Clewell HJ. 2010. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278:256-267.
9. Brightman FA, Leahy DE, Searle GE, Thomas S. 2006. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab. Dispos. 34:84-93. (Pubitemid 43042649)
10. Brocklebank JR, Namdari R, Law FC. 1997. An oxytetracycline residue depletion study to assess the physiologically based pharmokinetic (PBPK) model in farmed Atlantic salmon. Can. Vet. J. 38:645-646.
11. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13:407-484. (Pubitemid 27314117)
12. Chiu WA, Okino MS, Evans MV. 2009. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol. Appl. Pharmacol. 241:36-60.
13. Christensen EI, Birn H. 2002. Megalin and cubilin: multifunctional endocytic receptors. Nat. Rev. Mol. Cell Biol. 3:256-266. (Pubitemid 34619261)
14. Clewell RA, Clewell HJ, III. 2008. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul. Toxicol. Pharmacol. 50:129-143. (Pubitemid 50013231)
15. Craig WA, Redington J, Ebert SC. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
16. Craigmill AL. 2003. A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. J. Vet. Pharmacol. Ther. 26:55-63. (Pubitemid 36308202)
17. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095. (Pubitemid 23211439)
18. DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early life stage differences in the disposition of environmental toxicants. Regul. Toxicol. Pharmacol. 51:66-86.
19. Fiegel J, et al. 2008. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 25:805-811. (Pubitemid 351661830)
20. Fu LM, Shinnick TM. 2007. Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide GeneChips. J. Infect. 54:277-284. (Pubitemid 46238171)
21. Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME. 1986. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J. Pharmacol. Exp. Ther. 236:470-475. (Pubitemid 16184244)
22. Global Alliance for TB Drug Development. 2008. Capreomycin. Tuberculosis 88:89-91.
23. Goutelle S, Bourguignon L, Jelliffe RW, Conte JE, Jr., Maire P. 2011. Mathematical modeling of pulmonary tuberculosis therapy: insights from a prototype model with rifampin. J. Theor. Biol. 282:80-92.
24. Hall RG, Leff RD, Gumbo T. 2009. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1468-1481.
25. Heifets L, Simon J, Pham V. 2005. Capreomycin is active against non-replicating M. tuberculosis. Ann. Clin. Microbiol. Antimicrob. 4:6.
26. Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544. (Pubitemid 15211649)
27. Honeybourne D. 1994. Antibiotic penetration into lung tissues. Thorax 49:104-106. (Pubitemid 24115439)
28. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45:511-542.
29. Kanazawa Y, Kuramata T. 1964. Measurement of capreomycin in body fluids. J. Antibiot. B 17:190-192.
30. Kirman CR, Sweeney LM, Meek ME, Gargas ML. 2003. Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol. 38:345-367. (Pubitemid 37414823)
31. Knaak JB, al-Bayati MA, Raabe OG. 1995. Development of partition coefficients, Vmax and Km values, and allometric relationships. Toxicol. Lett. 79:87-98.
32. Laplanche R, Meno-Tetang GM, Kawai R. 2007. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J. Pharmacokinet. Pharmacodyn. 34:373-400. (Pubitemid 46873032)
33. Le Conte P, et al. 1994. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob. Agents Chemother. 38:2695-2701. (Pubitemid 24374423)
34. Lee SH, et al. 2003. The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles. Int. J. Antimicrob. Agents 22:81-83. (Pubitemid 36808724)
35. Leggett JE, et al. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292. (Pubitemid 19049368)
36. Lyons MA, Yang RSH, Mayeno AN, Reisfeld B. 2008. Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data. Environ. Health Persp. 116:1040-1046.
37. Metzler C. 2010. Physiologically based pharmacokinetic modeling for prediction of pharmacokinetic parameters of capreomycin. Master's thesis. Colorado State University, Fort Collins, CO.
38. Mingeot-Leclercq MP, Tulkens PM. 1999. Aminoglycosides: nephrotoxicity. Antimicrob. Agents Chemother. 43:1003-1012. (Pubitemid 29214718)
39. Mork AK, Johanson G. 2010. Chemical-specific adjustment factors for intraspecies variability of acetone toxicokinetics using a probabilistic approach. Toxicol. Sci. 116:336-348.
40. Mouton JW, et al. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
41. Nagai J, Takano M. 2004. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab. Pharmacokinet. 19:159-170.
42. Tuberculosis Working Group of NIAID. 2007. NIAID research agenda: multidrug-resistant and extensively drug-resistant tuberculosis. NIAID, Bethesda, MD.
43. Organick AB, Wilson EM. 1968. Multiple drugs in retreatment of chronic pulmonary tuberculosis. Results with capreomycin and ethambutol. Dis. Chest 53:560-570.
44. Peloquin CA. 1993. Pharmacology of the antimycobacterial drugs. Med. Clin. North Am. 77:1253-1262. (Pubitemid 23340433)
45. Peters SA. 2012. Physiologically based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. Wiley, Hoboken, NJ.
46. Reddy MB. 2005. Physiologically based pharmacokinetic modeling: science and applications. Wiley-Interscience, Hoboken, NJ.
47. Reisfeld B, Mayeno AN, Lyons MA, Yang RSH. 2007. Physiologically-based pharmacokinetic and pharmacodynamic modeling, p. xxii. In Ekins S (ed), Computational toxicology: risk assessment for pharmaceutical and environmental chemicals. Wiley-Interscience, Hoboken, NJ.
48. Schmitz C, et al. 2002. Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol. Chem. 277:618-622. (Pubitemid 34952099)
49. Ward DT, McLarnon SJ, Riccardi D. 2002. Aminoglycosides increase intracellular calcium levels and ERK activity in proximal tubular OK cells expressing the extracellular calcium-sensing receptor. J. Am. Soc. Nephrol. 13:1481-1489. (Pubitemid 34579237)
50. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. WHO, Geneva, Switzerland.
51. World Health Organization. 2010. Stop TBInitiative (World Health Organization): treatment of tuberculosis. Guidelines for national programmes, 4th ed. World Health Organization, Geneva, Switzerland.
52. Zietse R, Zoutendijk R, Hoorn EJ. 2009. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat. Rev. Nephrol. 5:193-202.